JMP cuts Nuvelo to market perform

Nuvelo, Inc. was downgraded to market perform from market outperform by JMP Securities analyst Charles Duncan. Alfimeprase for peripheral arterial occlusion receives fast track status, but a lack of transformative clinical news is expected for the rest of 2006. Shares of the Sunnydale, Calif., biopharmaceutical company were down 18 cents, or 1.16%, at $15.39 on volume of 1,894,857 shares versus the three-month running average of 652,962 shares. (Nasdaq: NUVO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.